Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,292 papers from all fields of science
Search
Sign In
Create Free Account
Gemcitabine-Erlotinib Regimen
Known as:
Gemcitabine-Tarceva Regimen
A chemotherapy combination used for the treatment of locally advanced and metastatic pancreatic cancer. It includes the drugs gemcitabine…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Erlotinib Hydrochloride
Gemcitabine hydrochloride
Pancreatic carcinoma
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The Use of Ziziphus spina-christi Extract in Treating Erlotinib (Tarceva®) Associated Rash: A Case Report
A. M. Alzahrani
,
A. Alzahrani
,
A. Alsharm
Case Reports in Oncology
2019
Corpus ID: 210086268
The most common side effect for cancer patients using epidermal growth factor receptor inhibitors (EGFRI) is the development of…
Expand
2015
2015
Of the Big Daddy, the Underdog, the Mother Hen, and the Scapegoats: Balancing Pharmaceutical Innovation and Access to Healthcare in the Enforcement of Compulsory Patent Licensing in India, its…
M. Chopra
2015
Corpus ID: 169500374
2009
2009
9175 The effectiveness of erlotinib (Tarceva®) treatment in KRAS negative lung adenocarcinomas – preliminary results of an observational cohort study
G. Ostoros
,
V. Sárosi
,
G. Losonczy
,
E. Tolnay
,
L. Molnar
2009
Corpus ID: 72520765
2008
2008
Second-Line-Therapie des nichtkleinzelligen Lungenkarzinoms (NSCLC) – eine retrospektive Kostenanalyse
U. Gatzemeier
,
O. Pirk
,
A. Gabriel
,
W. Kotowa
,
D. Heigener
2008
Corpus ID: 57718724
Fragestellung: Methoden: Ergebnisse: Schlussfolgerung: Objectives: Methods: Results: Conclusions:
2005
2005
Tarceva™ (erlotinib) exposure/effects (EE) analysis from a Phase III study in advanced NSCLC: Effect of smoking on the PK of erlotinib
M. Hamilton
,
J. Wolf
,
+9 authors
F. Shepherd
2005
Corpus ID: 53858666
6165 NCIC CTG BR21 was a randomized, double-blind, placebo-controlled study of erlotinib conducted in 731 NSCLC patients (pts…
Expand
2005
2005
Outils pharmacologiques du ciblage du récepteur du facteur de croissance épidermique et du VEGF
G. Milano
2005
Corpus ID: 70767112
Plusieurs anticorps monoclonaux diriges contre le REGF sont actuellement en evaluation clinique, en particulier le cetuximab…
Expand
Review
2005
Review
2005
Erlotinib (Tarceva®): A brief overview: The authors review erlotinib (Tarceva®) for the treatment of non-small-cell lung cancer.
D. Clay
,
Yvette M. Lipman
,
M. E. Bonk
2005
Corpus ID: 78268137
2004
2004
A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers.
P. Vasey
,
S. Kaye
,
+7 authors
K. Carty
Journal of Clinical Oncology
2004
Corpus ID: 978496
5017 Background: Epidermal growth factor receptor (HER1/EGFR) overexpression occurs in over 50% of advanced epithelial ovarian…
Expand
2004
2004
Erlotinib (Tarceva ® ) inhibits oral cavity carcinoma and synergizes with cisplatin and ionizing radiation in vitro
Raymond A Hinerman
,
W. Gao
,
H. Ramadan
,
C. Cunningham
,
Peilin Zhang
2004
Corpus ID: 56303784
Epidermal growth factor (EGF) plays important roles in the growth and development of normal epidermis and numerous malignant…
Expand
2003
2003
O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung…
A. Sandler
,
E. Mininberg
,
+7 authors
David H. Johnson
2003
Corpus ID: 72628992
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE